April price cut hits Japanese growth
This article was originally published in Scrip
Executive Summary
Japan's total prescription market grew by a modest 2.4% in the three months to June 30th, rising to ¥2,046.8 billion ($18.85 billion) at reimbursement prices but constrained by the regular biennial April 1st general price cut. This saw reimbursement levels cut by an average of 5.2%, with one-off reductions of around 10% for fast-growing angiotensin II antagonists.